Updates on Chronic Lymphocytic Leukemia

Dear Colleagues,

Chronic lymphocytic leukemia (CLL) is a heterogeneous group of clonal B-cell lymphoproliferative diseases with various clinical courses and biological features, where microenvironment, phenotypic, chromosomal, and molecular alterations concur with disease development and progression. Risk stratification and prognostication is performed using the CLL-International Prognostic Index, which combines clinical, chromosomal, molecular, and serological alterations and can help in clinical management and therapeutic decisions. Indeed, the discovery of novel disease biomarkers can also identify novel targeted therapies that can markedly improve clinical outcomes of CLL, as described for ibrutinib, idelalisib, and venetoclax.

We are pleased to invite you to a Special Issue of Cancers on the topic of Updates on Chronic Lymphocytic Leukemia.

This Special Issue focuses on novel diagnostic and prognostic markers and recent therapeutic advances of CLL. Articles shining a light on the mechanisms of drug resistance and disease progression are also welcome. Authors are encouraged to submit their original research studies concerning this topic. Review articles will also be taken into consideration.

Topics include, but are not limited to, the following:

• Recent development in molecular biomarkers predicting prognosis of CLL;
• Minimal residual disease in CLL;
• Targeted therapies and novel therapeutic strategies;
• Recent advances in management of CLL;
• Mechanism of drug resistance and novel therapies to overcome the resistance.

We look forward to receiving your contributions.

Prof. Dr. Carmine Selleri
Dr. Giovanni D'Arena
Dr. Luca Laurenti 
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.